Merck's Bridion Approval Carries Several Post-Market Requirements
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck must conduct studies to determine likely non-responders, assess occurrence of hypersensitivity or anaphylaxis, evaluate risk of cardiac arrhythmias, and study sugammadex's effects in morbidly obese patients.
You may also be interested in...
Should Obese Patients Be Included In Every Drug Development Program?
FDA officials question whether modeling tools can predict which drugs have different disposition in obese populations. They say physiologically-based pharmacokinetic data cannot be used as a surrogate for actual clinical trial data at this time.
Merck's Sugammadex Sails Through FDA Panel But Faces Post-Approval Studies
Advisory committee suggests post-marketing epidemiological studies in higher risk patients to further assess risks of hypersensitivity, anaphylaxis and cardiac rhythm disorders with the neuromuscular blockade reversal agent.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.